MX2016004660A - Composiciones de peptido novedosas. - Google Patents

Composiciones de peptido novedosas.

Info

Publication number
MX2016004660A
MX2016004660A MX2016004660A MX2016004660A MX2016004660A MX 2016004660 A MX2016004660 A MX 2016004660A MX 2016004660 A MX2016004660 A MX 2016004660A MX 2016004660 A MX2016004660 A MX 2016004660A MX 2016004660 A MX2016004660 A MX 2016004660A
Authority
MX
Mexico
Prior art keywords
compositions
peptides
amino acids
formula
novel peptide
Prior art date
Application number
MX2016004660A
Other languages
English (en)
Spanish (es)
Inventor
Franklin Richard
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of MX2016004660A publication Critical patent/MX2016004660A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2016004660A 2013-10-11 2014-10-01 Composiciones de peptido novedosas. MX2016004660A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361890056P 2013-10-11 2013-10-11
US201461940095P 2014-02-14 2014-02-14
PCT/US2014/058646 WO2015054006A2 (en) 2013-10-11 2014-10-01 Novel peptide compositions

Publications (1)

Publication Number Publication Date
MX2016004660A true MX2016004660A (es) 2016-11-14

Family

ID=52813728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004660A MX2016004660A (es) 2013-10-11 2014-10-01 Composiciones de peptido novedosas.

Country Status (13)

Country Link
EP (1) EP3054967A4 (enExample)
JP (1) JP2017501967A (enExample)
KR (1) KR20160065969A (enExample)
CN (1) CN105828831A (enExample)
AU (1) AU2014332346B2 (enExample)
BR (1) BR112016007816A2 (enExample)
CA (1) CA2926641A1 (enExample)
CL (1) CL2016000836A1 (enExample)
IL (1) IL244956B (enExample)
MX (1) MX2016004660A (enExample)
RU (1) RU2016112931A (enExample)
SG (1) SG11201602661PA (enExample)
WO (1) WO2015054006A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6863362B2 (ja) * 2016-03-03 2021-04-21 不二製油株式会社 神経栄養因子の脳内分泌促進するための食品添加用組成物
EA201991699A1 (ru) * 2017-02-16 2020-01-21 Кареджен Ко., Лтд. Конъюгат салициловой кислоты и пептида

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
DE69738326T2 (de) 1996-07-12 2008-07-03 Mcgill University, Montreal Verbindungen und verfahren zur regulierung der zellanlagerung
WO2001053331A2 (en) 2000-01-24 2001-07-26 Adherex Technologies, Inc. Peptidomimetic modulators of cell adhesion
AU2002335657A1 (en) 2001-08-24 2003-03-10 Neuronz Biosciences, Inc. Neural regeneration peptide and methods for their use in treatment of brain damage
US7563862B2 (en) 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage
AU2003293807A1 (en) * 2002-12-24 2004-07-22 Algonomics N.V. Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
EP1685151A4 (en) * 2003-10-31 2009-04-22 Neuren Pharmaceuticals Ltd PEPTIDES FOR THE REGENERATION OF NERVES AND METHOD FOR THEIR APPLICATION IN THE TREATMENT OF BRAIN DAMAGES
WO2007011595A2 (en) 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
WO2012006598A2 (en) * 2010-07-09 2012-01-12 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
KR20140140546A (ko) * 2012-02-10 2014-12-09 타릭스 파마슈티컬스 엘티디. 말초 혈관 질환의 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
CN105828831A (zh) 2016-08-03
IL244956B (en) 2019-10-31
SG11201602661PA (en) 2016-05-30
KR20160065969A (ko) 2016-06-09
EP3054967A4 (en) 2017-04-19
BR112016007816A2 (pt) 2017-12-05
WO2015054006A2 (en) 2015-04-16
AU2014332346B2 (en) 2019-01-24
CA2926641A1 (en) 2015-04-16
EP3054967A2 (en) 2016-08-17
WO2015054006A3 (en) 2015-06-04
JP2017501967A (ja) 2017-01-19
AU2014332346A1 (en) 2016-05-05
IL244956A0 (en) 2016-05-31
RU2016112931A (ru) 2017-11-16
CL2016000836A1 (es) 2016-09-16
RU2016112931A3 (enExample) 2018-06-20

Similar Documents

Publication Publication Date Title
PH12014501924A1 (en) Xten conjugate compositions and methods of making same
PH12017500866A1 (en) Targeted xten conjugate compositions and methods of making same
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MY187047A (en) Selective pyy compounds and uses thereof
MX2019000566A (es) Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña.
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
IN2013MU03583A (enExample)
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
MX2013001677A (es) Formulaciones estables de linaclotida.
IN2014DN00101A (enExample)
MX2018014023A (es) Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos.
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
PH12019550241A1 (en) Mic-1 compounds and uses thereof
CY1119036T1 (el) Νεοι αγωνιστες του υποδοχεα τυπου 2 της αγγειοτενσινης (ατ2) και χρησεις τους
MX2020012989A (es) Agente terapeutico para la fibrosis.
TN2013000386A1 (en) Suspension type topical formulations comprising cyclic depsipeptide
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
WO2015024022A3 (en) Designed peptides for tight junction barrier modulation
CL2021001479A1 (es) Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391)
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
MX2016004660A (es) Composiciones de peptido novedosas.
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
MX377823B (es) Composición nasal con capacidades de formación de película.
WO2019104062A8 (en) Polymorphs and uses thereof